<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755142</url>
  </required_header>
  <id_info>
    <org_study_id>MC-ALS.8-I/GLI</org_study_id>
    <nct_id>NCT02755142</nct_id>
  </id_info>
  <brief_title>Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas</brief_title>
  <official_title>Clinical Phase I/II Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IKP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>medac GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is planned to detect a dose-efficacy relationship between the chosen dose levels
      of MC506/1 and the extent and quality of fluorescence in the tumour core in patients with
      newly diagnosed malignant glioma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">June 2001</completion_date>
  <primary_completion_date type="Actual">June 2001</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of a dose-efficacy relationship between the dose levels and the extent and quality of fluorescence in the tumour core (of newly diagnosed malignant glioma).</measure>
    <time_frame>Within 3 hours</time_frame>
    <description>After completion of resection, global fluorescence extent in the tumour core will be assessed by the first and second surgeon. It will be estimated whether approx. 0/3, 1/3, 2/3 or 3/3 of the tumour core is identified using standard white operation light were fluorescent (irrespective of fluorescence quality). The global quality of Gliolan induced tissue fluorescence within the tumour core will be recorded as being strong, weak or missing. As an objective control of the subjective assessment of the fluorescent quality, selected areas will be measured spectrometrically.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Brain Neoplasm</condition>
  <arm_group>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0,2 mg/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2,0 mg/Kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg/Kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gliolan</intervention_name>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <other_name>5-Aminolevulinic Acid Hydrochloride (5-ALA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Radiological suspicion of a malignant glioma with distinct ring- or garland shaped,
             contrast agent-enhancing tumour structures and a core area of reduced intensity in the
             MRI (tumour necrosis)

          -  Indication for surgical tumour resection

          -  First operation of the tumour, no other tumour-specific pre-treatment

          -  Karnofsky Performance Scale 70%

          -  Patient's written informed consent

          -  Age 18-75 years

        Exclusion Criteria:

          -  Porphyria, hypersensitivity to porphyrins

          -  Renal insufficiency:

               -  Creatinine &gt; 2.0 mg/dl

          -  Hepatic insufficiency:

               -  Bilirubin &gt; 3 mg/dl

               -  Quick test &lt; 60 %

               -  GT &gt; 100 U/I

          -  Other known malignancy (except basaliomas)

        Women:

          -  Existing/planned pregnancy (to be checked by a pregnancy test if of child-bearing
             age)/lactation or inadequate contraception (hormone cycle regulation pill or condom)

        Men:

          -  Inadequate contraception (condom)

          -  Dementia or mental condition making it impossible to understand the therapy and
             therefore prohibiting written consent

          -  Simultaneous participation or participation in another clinical trial in the preceding
             30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>May 20, 2016</last_update_submitted>
  <last_update_submitted_qc>May 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

